tradingkey.logo

Ratio Therapeutics Has Successfully Dosed The First Cohort

ReutersDec 16, 2025 1:41 PM

-

  • RATIO THERAPEUTICS HAS SUCCESSFULLY DOSED THE FIRST COHORT IN ITS PHASE 1/2 STUDY EVALUATING A NOVEL FAP-TARGETED RADIOPHARMACEUTICAL IN PATIENTS WITH LATE-STAGE AGGRESSIVE SARCOMAS

Further company coverage: [ ]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI